All In Biotech

Drug Trial Radar · NCT06095583

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 756 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

756

Planned (sponsor's estimate)

Start

Nov 15, 2023

Primary completion

Jul 31, 2027

Study completion Jul 31, 2029

Sponsor

Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death protein-1 (PD-1). Neither drug is approved for treatment of This combination regimen is investigational in limited stage-small cell lung cancer in any country.

Conditions

  • Limited-stage Small Cell Lung Cancer (LS-SCLC)

Interventions

  • Tifcemalimab injectionDrug

    200mg once every 3weeks

  • toripalimab injectionDrug

    240mg once every 3 weeks

  • Placebo for TifcemalimabDrug

    every 3weeks

  • Placebo for toripalimabDrug

    every 3weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: up to 3years
  2. OSTime frame: up to 3years
  3. Progression-free survival (PFS)Time frame: up to 2years
  4. Progression-free survival (PFS)Time frame: up to 2years

Locations

76 sites in 6 countries. Site status is shown where the registry gives one.

  • Anyang Tumor Hospital

    Anyang, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, China · Not yet recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, China · Recruiting

  • Sichuan cancer hospital

    Chengdu, China · Not yet recruiting

  • Chongqing University Cancer Hospital

    Chongqing, China · Recruiting

  • Peking University Shenzhen Hospital

    Guangdong, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, China · Recruiting

  • No. 1 Bandong Road, Gongshu District, Hangzhou

    Hangzhou, China · Recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • The First Affiliated Hospital of Ustc

    Hefei, China · Recruiting

  • Henan Cancer Hospital

    Henan, China · Not yet recruiting

  • Affiliated Hospital of Jining Medical University

    Jining, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Not yet recruiting

  • Liaoning cancer hospital

    Shenyang, China · Not yet recruiting

  • Shanxi Cancer hospital

    Taiyuan, China · Recruiting

  • Taizhou Hospital of Zhejiang Province

    Taizhou, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Recruiting

  • Hubei Cancer Hospital (Hubei Cancer Research Institute)

    Wuhan, China · Recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China · Not yet recruiting

  • General Hospital of Ningxia Medical University

    Yinchuan, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Xiangya Hospital Central South University

    Changsha, Hunan, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Shandong Cancer Hospital & Institute

    Jinan, Shandong, China · Recruiting

  • "TIM - Tbilisi Institute of Medicine" LTD

    Tbilisi, Georgia · Not yet recruiting

  • ICO-Institute of Clinical Oncology - Hospital

    Tbilisi, Georgia · Recruiting

  • LTD "Israel-Georgian Medical Research Clinic Healthycore"

    Tbilisi, Georgia · Recruiting

  • LTD "New Hospitals"

    Tbilisi, Georgia · Recruiting

  • ISR-GEO Med Res Clin Healthycore

    Tbilisi, K'alak'i T'bilisi, Georgia · Recruiting

  • Ltd New Hospitals

    Tbilisi, K'alak'i T'bilisi, Georgia · Recruiting

  • Multprofil Clinic Consilium Medulla

    Tbilisi, K'alak'i T'bilisi, Georgia · Recruiting

  • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic

    Tbilisi, K'alak'i T'bilisi, Georgia · Recruiting

  • Jeroen Bosch Ziekenhuis

    's-Hertogenbosch, Netherlands · Not yet recruiting

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.